Story perspectives

New Anti-Aging Drug Extends Yeast Lifespan, Researchers Discover

10/10/2025

44 9

Summary

Story summary

Researchers from Queen Mary University of London discovered a new anti-aging drug class, Rapalink-1, which extends yeast lifespan by targeting the Target of Rapamycin (TOR) pathway.
The TOR pathway is essential for growth and aging across various species, including humans.
Rapalink-1 enhances the conversion of agmatine, produced by gut bacteria, into beneficial chemicals that may affect aging.
Researchers advise caution against using agmatine supplements for longevity due to potential negative effects.
The findings were published in the journal Communications Biology.

1 of 1

Story summary

Researchers from Queen Mary University of London discovered a new anti-aging drug class, Rapalink-1, which extends yeast lifespan by targeting the Target of Rapamycin (TOR) pathway.
The TOR pathway is essential for growth and aging across various species, including humans.
Rapalink-1 enhances the conversion of agmatine, produced by gut bacteria, into beneficial chemicals that may affect aging.
Researchers advise caution against using agmatine supplements for longevity due to potential negative effects.
The findings were published in the journal Communications Biology.